So the statistical takeaway as I see it is in this

So the statistical takeaway as I see it is in this comp:

Quote:

---

Pretreated mTNBC has a poor prognosis whether treated with chemotherapy (French ESME program, ≥2 systemic therapies, median overall survival (mOS) ∼6 months, survival 1 year ∼25%, 2 years ∼10%, 3 years ∼7%), pembrolizumab + standard chemotherapy (mOS=10.8 months, 1 year ∼25%, 2 years 10%), or sacituzumab govitecan (ASCENT) (mOS=∼11.8 months, 1 year ∼25%, 2 years 20%).....

Leronlimab... pooled survival (1 yr. 41.3%, 2 yr. 24.8%, 3 yr 19.8%)

---

So two year survival in other treatments 10%, 10%, and 20%. Leron 24.88%
Leron has a 3 year survival rate that is very close to Troldelvy's 2 year survival rate.